Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China flag China · Delayed Price · Currency is CNY
25.22
+0.07 (0.28%)
At close: Aug 27, 2026

SHE:300937 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
385.07409.36386.88374.86457.82153.78
Short-Term Investments
-9.274.120.83--
Trading Asset Securities
130.82-1.547-
Cash & Short-Term Investments
515.89418.64392.5379.69464.82153.78
Cash Growth
53.21%6.66%3.37%-18.32%202.27%34.62%
Accounts Receivable
433.3210.47229196.54146.2657.75
Other Receivables
23.2543.6485.1867.6215.9325.6
Receivables
456.55254.11314.18264.16162.1883.35
Inventory
464.53575.19522.59561.24446.78468.23
Other Current Assets
168.5154.64142.38171.35190.01126.33
Total Current Assets
1,6051,4031,3721,3761,264831.68
Property, Plant & Equipment
141.43143.75161.8154.05164.95174.76
Long-Term Investments
57.8561.4141.2328.2522.421.58
Goodwill
14.213.7118.7116.4716.362.52
Other Intangible Assets
37.5743.0248.0346.4350.6542.06
Long-Term Deferred Tax Assets
46.0436.9827.3415.238.863.69
Long-Term Deferred Charges
29.6821.132.8243.9213.765.34
Other Long-Term Assets
--1.576.2750.83105.43
Total Assets
1,9321,7231,7031,6871,5921,187

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
712.93417.41333.22359.66370.54184.1
Accrued Expenses
11.8823.3432.2131.9822.1910.98
Short-Term Debt
282.6324.17372.32320.74235.84119.36
Current Portion of Leases
-6.536.774.25.244.7
Current Income Taxes Payable
21.2419.646.144.997.871.19
Current Unearned Revenue
30.7560.7849.8253.5778.8529.77
Other Current Liabilities
46.0652.2437.8925.9832.1827.9
Total Current Liabilities
1,118904.11838.35801.12752.7378
Long-Term Leases
4.414.049.764.692.545.75
Long-Term Unearned Revenue
4.194.354.6856.326.1
Long-Term Deferred Tax Liabilities
12.8410.9813.0813.3410.079.29
Other Long-Term Liabilities
6.140.470.356.88--
Total Liabilities
1,146923.95866.22831.02771.64399.13

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
95.6795.6795.6795.6795.6795.67
Additional Paid-In Capital
474474474.01474.01475.62475.56
Retained Earnings
241.61251.14273.55284.55244.15202.28
Comprehensive Income & Other
-----1.5-
Total Common Equity
811.28820.81843.23854.22813.94773.51
Minority Interest
-24.86-22.21-6.311.826.0314.43
Shareholders' Equity
786.42798.6836.93856.04819.98787.94
Total Liabilities & Equity
1,9321,7231,7031,6871,5921,187

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
299.79334.74388.85329.63243.62129.8
Net Cash (Debt)
216.183.893.6550.06221.2123.98
Net Cash Growth
1068.09%2200.11%-92.72%-77.37%822.60%-67.68%
Net Cash Per Share
2.250.880.050.522.320.26
Filing Date Shares Outstanding
107.0995.6795.6795.6795.6795.67
Total Common Shares Outstanding
107.0995.6795.6795.6795.6795.67
Working Capital
487.24498.46533.3575.32511.1453.68
Book Value Per Share
7.588.588.818.938.518.09
Tangible Book Value
759.51764.07776.49791.32746.94728.93
Tangible Book Value Per Share
7.097.998.128.277.817.62
Buildings
-116.62116.61116.57118.19117.76
Machinery
-97.7294.9682.3181.9978.87
Construction In Progress
-0.150.52.211.84-